Humacyte (HUMA) Stock Price Target 2026

The average analyst price target for Humacyte is $5.33, 848.9% above the current price. Of 7 analysts, 6 rate it Buy and 1 Hold. Targets range from $0.50 to $15. The latest change came on Oct 7, 2026, when Barclays initiated coverage of Humacyte with an Equal-Weight rating and a $0.50 price target.

The Average Analyst Price Target for Humacyte is $5.33.

Price Target Range — 13 Quarters

Analyst Consensus — 7 Analysts

6Buy

1Hold

Consensus RatingBuy# Analysts7Avg. Consensus PT$5.33Upside to Avg. PT+848.9%

Rating Trend — Last 9 Months

Latest Upgrades and Downgrades for Humacyte Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Nov 10, 2026	BTIG	Ryan Zimmerman	Maintained	Buy	$2
Oct 7, 2026	Barclays	Christopher Pasquale	Initiate	Equal-Weight	$1
Aug 13, 2026	Benchmark	Bruce D. Jackson	PT Cut	Speculative Buy	$2→$1
Jul 28, 2026	BTIG	Ryan Zimmerman	Maintained	Buy	$2
Jun 17, 2026	TD Cowen	Joshua Jennings	PT Cut	Buy	$2→$1
Jun 16, 2026	BTIG	Ryan Zimmerman	Maintained	Buy	$2
Jun 11, 2026	HC Wainwright & Co.	Swayampakula Ramakanth	PT Raise	Buy	$3→$4
Jun 8, 2026	BTIG	Ryan Zimmerman	Maintained	Buy	$2
Jun 1, 2026	Benchmark	Bruce D. Jackson	PT Raise	Speculative Buy	$1→$2
May 26, 2026	HC Wainwright & Co.	Swayampakula Ramakanth	Maintained	Buy	$3
May 14, 2026	TD Cowen	Joshua Jennings	PT Raise	Buy	$1→$2
May 13, 2026	BTIG	Ryan Zimmerman	PT Cut	Buy	$3→$2
Apr 28, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$25
Apr 28, 2026	BTIG	Ryan Zimmerman	Maintained	Buy	$3
Apr 24, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$25
Apr 21, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$25
Apr 8, 2026	Barclays	Matt Miksic	PT Cut	Overweight	$4→$2
Mar 31, 2026	Benchmark	Bruce D. Jackson	Downgrade	Buy→Speculative Buy	$10→$1
Mar 30, 2026	Piper Sandler	Allison Bratzel	PT Cut	Neutral	$3→$1
Mar 30, 2026	TD Cowen	Joshua Jennings	PT Cut	Buy	$4→$1